Baseline Characteristics by Treatment Group During the Priming Phases of the Combined Studies
| . | 1 mg DNA/ PBS (N = 42) . | 5 mg DNA/ PBS (N = 74) . | 5 mg DNA/ AlPO4 (N = 78) . | 5 mg DNA/ CRL 1005 (N = 89) . | Placebo/PBS (N = 41) . | Placebo/AlPO4 (N = 35) . |
|---|---|---|---|---|---|---|
| Gender (n [%]) | ||||||
| Male | 26 (62) | 38 (51) | 48 (62) | 53 (60) | 24 (59) | 17 (49) |
| Female | 16 (38) | 36 (49) | 30 (38) | 36 (40) | 17 (41) | 18 (51) |
| Age (years) | ||||||
| Median | 34 | 37 | 32 | 37 | 39 | 37 |
| Range | 18–55 | 19–53 | 18–50 | 20–50 | 18–55 | 18–50 |
| Asian/Pacific | 1 (2) | 0 (0) | 4 (5) | 2 (2) | 0 (0) | 0 (0) |
| Racial/Ethnic Origin (n [%]) | ||||||
| Black | 5 (12) | 7 (9) | 4 (5) | 6 (7) | 4 (10) | 3 (9) |
| Caucasian | 34 (81) | 63 (85) | 67 (86) | 78 (88) | 35 (85) | 31 (89) |
| Hispanic | 2 (5) | 3 (4) | 2 (3) | 2 (2) | 1 (2) | 1 (3) |
| Indian | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) |
| Native American | 0 (0) | 1 (1) | 0 (0) | 1 (1) | 0 (0) | 0 (0) |
| Multiracial | 0 (0) | 0 (0) | 1 (1) | 0 (0) | 0 (0) | 0 (0) |
| . | 1 mg DNA/ PBS (N = 42) . | 5 mg DNA/ PBS (N = 74) . | 5 mg DNA/ AlPO4 (N = 78) . | 5 mg DNA/ CRL 1005 (N = 89) . | Placebo/PBS (N = 41) . | Placebo/AlPO4 (N = 35) . |
|---|---|---|---|---|---|---|
| Gender (n [%]) | ||||||
| Male | 26 (62) | 38 (51) | 48 (62) | 53 (60) | 24 (59) | 17 (49) |
| Female | 16 (38) | 36 (49) | 30 (38) | 36 (40) | 17 (41) | 18 (51) |
| Age (years) | ||||||
| Median | 34 | 37 | 32 | 37 | 39 | 37 |
| Range | 18–55 | 19–53 | 18–50 | 20–50 | 18–55 | 18–50 |
| Asian/Pacific | 1 (2) | 0 (0) | 4 (5) | 2 (2) | 0 (0) | 0 (0) |
| Racial/Ethnic Origin (n [%]) | ||||||
| Black | 5 (12) | 7 (9) | 4 (5) | 6 (7) | 4 (10) | 3 (9) |
| Caucasian | 34 (81) | 63 (85) | 67 (86) | 78 (88) | 35 (85) | 31 (89) |
| Hispanic | 2 (5) | 3 (4) | 2 (3) | 2 (2) | 1 (2) | 1 (3) |
| Indian | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) |
| Native American | 0 (0) | 1 (1) | 0 (0) | 1 (1) | 0 (0) | 0 (0) |
| Multiracial | 0 (0) | 0 (0) | 1 (1) | 0 (0) | 0 (0) | 0 (0) |
Abbreviations: N, number of vaccinated subjects; n, number of subjects in each category; PBS, phosphate-buffered saline.
Baseline Characteristics by Treatment Group During the Priming Phases of the Combined Studies
| . | 1 mg DNA/ PBS (N = 42) . | 5 mg DNA/ PBS (N = 74) . | 5 mg DNA/ AlPO4 (N = 78) . | 5 mg DNA/ CRL 1005 (N = 89) . | Placebo/PBS (N = 41) . | Placebo/AlPO4 (N = 35) . |
|---|---|---|---|---|---|---|
| Gender (n [%]) | ||||||
| Male | 26 (62) | 38 (51) | 48 (62) | 53 (60) | 24 (59) | 17 (49) |
| Female | 16 (38) | 36 (49) | 30 (38) | 36 (40) | 17 (41) | 18 (51) |
| Age (years) | ||||||
| Median | 34 | 37 | 32 | 37 | 39 | 37 |
| Range | 18–55 | 19–53 | 18–50 | 20–50 | 18–55 | 18–50 |
| Asian/Pacific | 1 (2) | 0 (0) | 4 (5) | 2 (2) | 0 (0) | 0 (0) |
| Racial/Ethnic Origin (n [%]) | ||||||
| Black | 5 (12) | 7 (9) | 4 (5) | 6 (7) | 4 (10) | 3 (9) |
| Caucasian | 34 (81) | 63 (85) | 67 (86) | 78 (88) | 35 (85) | 31 (89) |
| Hispanic | 2 (5) | 3 (4) | 2 (3) | 2 (2) | 1 (2) | 1 (3) |
| Indian | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) |
| Native American | 0 (0) | 1 (1) | 0 (0) | 1 (1) | 0 (0) | 0 (0) |
| Multiracial | 0 (0) | 0 (0) | 1 (1) | 0 (0) | 0 (0) | 0 (0) |
| . | 1 mg DNA/ PBS (N = 42) . | 5 mg DNA/ PBS (N = 74) . | 5 mg DNA/ AlPO4 (N = 78) . | 5 mg DNA/ CRL 1005 (N = 89) . | Placebo/PBS (N = 41) . | Placebo/AlPO4 (N = 35) . |
|---|---|---|---|---|---|---|
| Gender (n [%]) | ||||||
| Male | 26 (62) | 38 (51) | 48 (62) | 53 (60) | 24 (59) | 17 (49) |
| Female | 16 (38) | 36 (49) | 30 (38) | 36 (40) | 17 (41) | 18 (51) |
| Age (years) | ||||||
| Median | 34 | 37 | 32 | 37 | 39 | 37 |
| Range | 18–55 | 19–53 | 18–50 | 20–50 | 18–55 | 18–50 |
| Asian/Pacific | 1 (2) | 0 (0) | 4 (5) | 2 (2) | 0 (0) | 0 (0) |
| Racial/Ethnic Origin (n [%]) | ||||||
| Black | 5 (12) | 7 (9) | 4 (5) | 6 (7) | 4 (10) | 3 (9) |
| Caucasian | 34 (81) | 63 (85) | 67 (86) | 78 (88) | 35 (85) | 31 (89) |
| Hispanic | 2 (5) | 3 (4) | 2 (3) | 2 (2) | 1 (2) | 1 (3) |
| Indian | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) |
| Native American | 0 (0) | 1 (1) | 0 (0) | 1 (1) | 0 (0) | 0 (0) |
| Multiracial | 0 (0) | 0 (0) | 1 (1) | 0 (0) | 0 (0) | 0 (0) |
Abbreviations: N, number of vaccinated subjects; n, number of subjects in each category; PBS, phosphate-buffered saline.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
